In Massachusetts, Xenetic Biosciences, Inc. has a new Chief Scientific Officer, Curtis A. Lockshin. Lockshin’s experience with research and development in the biopharmaceutical industry and his various biomaterials, therapeutics and biosensors inventions and patents will come in handy in his new role at Xenetic, a biopharmaceutical company. Lockshin was formerly a CEO, or served in other executive roles, at SciVac Therapuetics, VBI Vaccines, Guardum Pharmaceuticals, and OPKO Health. Lockshin will help Xenetic with their focus on next-gen biologic drugs and oncology therapeutics. Scott Maguire, Chief Executive Officer of Xenetic said in their press release “With our second important executive level appointment since our Nasdaq listing, Xenetic now has a structure to deliver on what we believe will be a transformational 2017.”
Latest article
UMaine lays off researchers focused on innovative wood waste materials
In Maine, nine researchers from the University of Maine’s Advanced Structures and Composites Center, including those focused on biobased materials innovation, are being laid...
COIM USA buys cashew nutshell-based polyols plant
In Texas, specialty chemical maker COIM USA has acquired a 20-acre property in New Boston from Palmer International. The acquisition includes existing logistics infrastructure,...
Split-gill mushroom eyed for biomaterial potential
In Switzerland, researchers at the Swiss Federal Laboratories for Materials Science and Technology have developed a biobased material from the living mycelium of the...